Category: Oncotarget

Oncotarget News

Open-Access Oncotarget Shifts to Continuous Publishing

January 6, 2022

As of 2022, the peer-reviewed and open-access journal Oncotarget has shifted to continuous publishing.—BUFFALO, NY, January 6, 2022 – Since its inception in 2010, Oncotarget ... read more

Oncotarget

Behind the Study: Cholera Toxin and Age-associated Obesity

December 23, 2021

Dr. Susan Erdman from Massachusetts Institute of Technology (MIT) discusses the 2019 research paper she co-authored, entitled, “Consuming cholera toxin counteracts age-associated obesity.”Behind the Study is... read more

Oncotarget

Behind the Study: Metformin and Rapamycin as Maintenance Therapy

December 13, 2021

Dr. Katherine Bever from Johns Hopkins University discusses a research paper she co-authored that was published by Oncotarget, “An exploratory study of metformin with or without rapamycin as maintenance therapy... read more

Oncotarget

Testimonial: Dr. Jennifer Sheng

December 10, 2021

Dr. Jennifer Sheng from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center shares her experience publishing "Innovating and expanding weight loss strategies for breast cancer survivors" with Oncotarget.Dr. Jennifer... read more

Oncotarget

Testimonial: Dr. Gina Abdelaal

December 3, 2021

Dr. Gina Abdelaal from Northumbria University discusses her experience publishing “Reversing oncogenic transformation with iron chelation,” with Oncotarget.Dr. Gina AbdelaalI selected Oncotarget because I remember... read more

Oncotarget

Testimonial: Dr. Monica Varun Tyagi

November 25, 2021

Dr. Monica Varun Tyagi discusses her experience publishing “GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3,” with Oncotarget.Dr. Monica... read more

Oncotarget

Behind the Study: P4HA1 Protein and Colorectal Cancer

November 22, 2021

Dr. Michael Roehrl from Memorial Sloan Kettering Cancer Center describes the research paper he co-authored that was published by Oncotarget on February 25, 2020, entitled, “Prolyl 4-hydroxylase... read more

Oncotarget

Testimonial: Dr. Michael Roehrl

November 19, 2021

Dr. Michael Roehrl from the Department of Pathology, Memorial Sloan Kettering Cancer Center discusses his experience while publishing the paper, “Prolyl 4-hydroxylase alpha 1 protein expression risk-stratifies early stage colorectal... read more

Oncotarget

Behind the Study: Benzophenone-3 Promotion of Mammary Tumorigenesis

November 15, 2021

Dr. Richard Schwartz describes the 2020 research paper he co-authored that was published by Oncotarget, entitled, “Benzophenone-3 promotion of mammary tumorigenesis is diet-dependent.”Behind the Study is a series... read more

Oncotarget

Testimonial: Dr. Reshma Sundar and Dr. Marene Landström

November 12, 2021

Below is a transcript of testimonials by Dr. Reshma Sundar and Dr. Marene Landström from the Department of Medical Biosciences at Umeå University in Sweden on their... read more